ZYUS Life Sciences Announces Filing of Amended and Restated LIFE Offering Document

Executive Summary

• ZYUS Life Sciences filed an amended and restated offering document for its LIFE Offering on February 9, 2026, reopening the unit sale under the listed‑issuer financing exemption.
• The offering is being led by Canaccord Genuity Corp., which serves as lead agent and sole bookrunner.
• The updated prospectus is available on SEDAR+ and the company’s website; investors are urged to review it before committing capital.

Key Details

• Offering Document: Amended and Restated Offering Document dated February 9, 2026 for the LIFE Offering.
• Regulatory Basis: Filed pursuant to the “listed issuer financing exemption” under NI 45‑106 (section 5A.2) and Coordinated Blanket Order 45‑935.
• Previous Announcement: Re‑opens the offering previously announced on January 12, 2026.
• Lead Agent/Bookrunner: Canaccord Genuity Corp. (contact: [email protected]).
• Access to Documents: Available via the company’s profile on SEDAR+ (www.sedarplus.ca) and on the corporate website (www.zyus.com).
• Investor Action Required: Prospective investors must read the Amended and Restated Offering Document before making an investment decision.

Notable Quotes

(No executive quotes were included in the release.)